Search clinical trials for: CapeOX bevacizumab

Total 2610 results

Tang-Du Hospital

Not yet recruiting

Treatment of Low Locally Advanced Rectal Cancer With Radiotherapy Removal TNT Plus Neoadjuvant Therapy

Rectal Cancer
Shanghai Minimally Invasive Surgery Center

Withdrawn

Anlotinib Hydrochloride Combined With Capeox in the Neoadjuvant Treatment of Locally Advanced Rectal Cancer

Rectal Cancer | Anlotinib | Neoadjuvant Treatment
SUNHO（China）BioPharmaceutical CO., Ltd.

Recruiting

To Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Metastatic Colorectal Cancer

HER2 Gene Mutation

China
Sun Yat-sen University

Recruiting

Neoadjuvant FOLFOXIRI Versus Immediate Surgery for Stage II and III Colon Cancers

Colon Cancer Stage II | Colon Cancer Stage III

China
West China Hospital

Recruiting

Capeox Regimen Combined With Sintilimab and Bevacizumab for Gastric Cancer

Stomach Neoplasm

China
Huazhong University of Science and Technology

Recruiting

SBRT Sequential CapeOX Regimen Combined With Bevacizumab and Sintilimab in First-line Treatment of mCRC

Metastatic Colorectal Cancer

China
Sun Yat-sen University
Guangzhou Burning Rock Dx Co., Ltd.

Recruiting

MRD-guided Deferred Adjuvant Therapy in Resectable Early-stage Colon Cancer (MIRROR)

Colorectal Cancer

China
Henan Cancer Hospital

Recruiting

Fruquintinib in Combination With Sintilimab and CAPEOX as First-line Treatment for G/GEJ Cancer

Metastatic Gastroesophageal Junction Adenocarcinoma

China
Koen Rovers
Hoffmann-La Roche; Comprehensive Cancer Centre The Netherlands; Dutch Cancer...

Recruiting

Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases (CAIRO6)

Colorectal Cancer | Peritoneal Neoplasms | Colorectal Neoplasm | Peritoneal Carcinomatosis | Colorectal Carcinoma | Peritoneal Cancer | Peritoneal Metastases | Colorectal Adenocarcinoma | Colorectal Neoplasms Malignant | Peritoneal Neoplasm Malignant Secondary Carcinomatosis | Peritoneal Neoplasm Malignant...

Netherlands, Belgium
Chinese PLA General Hospital

Recruiting

CAPOX + Bevacizumab + Tirelizumab Treating PDL1 CPS < 5 GEA

Advanced Gastroesophageal Adenocarcinoma | First-line Therapy | PDL1 CPS < 5

China
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Active, not recruiting

A Trial of SHR1701 Plus Chemotherapy in Patients With Gastric or Gastroesophageal Cancer

Gastric or Gastroesophageal Junction Cancer

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Clinical Study to Compare the Efficacy and Safety of AK105 Plus Anlotinib and Capecitabine/Oxaliplatin (CapeOx) , Anlotinib Plus CapeOx, Bevacizumab Plus CapeOx

Unresectable Metastatic Colorectal Cancer

China
Sun Yat-sen University

Recruiting

Envafolimab Monotherapy or Envafolimab + CAPEOX as Neoadjuvant Therapy for Locally Advanced Colorectal Cancer

Colon Cancer | Neoadjuvant Therapy | Immunotherapy

China
fan li

Not yet recruiting

Neoadjuvant Immunotherapy in Locally Advanced Colon Cancers

Colon Cancer | Immunotherapy

China
Xijing Hospital

Not yet recruiting

Adjuvant Treatment of Digestive Tract Tumors (ATDTT)

Adjuvant Treatment
Nanfang Hospital, Southern Medical University

Not yet recruiting

Cadonilimab Plus CapeOX as First-Line Treatment for Advanced GC/GEJC With High TMEscore

Gastric Cancer

China
Sixth Affiliated Hospital, Sun Yat-sen University

Recruiting

Adjuvant Chemotherapy Combined With Targeted Therapy or Not in the T3-4N2 Colorectal Cancer Patients

Colorectal Cancer | Chemotherapy Effect

China
Canadian Cancer Trials Group

Completed

NEO: Neoadjuvant Chemotherapy, Excision and Observation for Early Rectal Cancer

Rectal Cancer

United States, Canada
Hospital Universitari de Bellvitge
Instituto de Salud Carlos III

Terminated

Resection vs no Resection of the Primary in Colorectal Cancer With Unresectable Metastases (CCRe-IV)

Colonic Cancer | Unresectable Metastasis Originating in Colonic Cancer

Spain
The First Hospital of Jilin University

Not yet recruiting

Total Neoadjuvant Chemoradiotherapy Plus Anti-PD-1 in Subperitoneal Patients With Locally Advanced Rectal CancerPatients With Locally Advanced Rectal Cancer: A Prospective, Single Arm, Exploratory Study

Locally Advanced Rectal Cancer | Anti-PD-1 | Total Neoadjuvant Treatment

China
GlaxoSmithKline

Completed

Study On Pazopanib When Given With FOLFOX6 (Fluorouracil, Oxaliplatin, Leucovorin) Or CapeOx (Capecitabine, Oxaliplatin)

Neoplasms, Colorectal

India, United Kingdom
Nanfang Hospital, Southern Medical University

Recruiting

Lenvatinib Plus Tislelizumab and CapeOX as First-Line Treatment for Advanced GC/GEJC With Positive PD-L1 and Low TMEscore

Gastric Cancer

China
National Cancer Centre, Singapore
Merck Sharp & Dohme LLC

Recruiting

Window of Opportunity Study in Colorectal Cancer

Colorectal Cancer

Singapore
GlaxoSmithKline

Recruiting

Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer (AZUR-2)

Colonic Neoplasms | Neoplasms, Colon

United States, Finland, France, Italy, Japan, Netherlands, Norway, Spain, Taiwan, United Kingdom, Australia, Belgium, Brazil, Germany, Greece, Sweden, Turkey, Canada, Korea, Republic of, Argentina, Hungary, Estonia, Portugal, Mexico, Pa...
West China Hospital
Sun Yat-sen University; Peking University Cancer Hospital & Institute; Second... and other collaborators

Recruiting

Comparison of the Pathological Effect Between 2 and 4 Cycles Neoadjuvant CAPOX for Low/Intermediate Risk II/III Rectal Cancer (COPEC)

Rectal Cancer | Neoadjuvant Chemotherapy

China
Ohio State University
Natreon, Inc.

Completed

Effects of Capros in Patients With Type-1 Diabetes (CarposT1D)

Type I Diabetes

United States
AskGene Pharma, Inc.
Jiangsu Aosaikang Pharmaceutical Co., Ltd.

Recruiting

ASKB589 in Combination With CAPOX and Sintilimab in Patients With Advanced, and Unresectable G/GEJ Cancer.

Gastric Cancer

China
Daping Hospital and the Research Institute of Surgery...

Recruiting

Multi-omics Sequencing in Neoadjuvant Immunotherapy of Gastrointestinal Tumors

Gastric Cancer | Rectal Cancer | Chemotherapy Effect | Radiotherapy | Immunotherapy

China
Medtronic Endovascular

Terminated

AVATR - Arteriovenous Access Thrombosis Removal With CAPERE Thrombectomy System (AVATR)

Arteriovenous Graft Thrombosis

Canada
Medtronic Endovascular

Terminated

CAPERE Thrombectomy System Post-Market Clinical Follow Up Study

Observational Study

United States
NRG Oncology
National Cancer Institute (NCI); Natera, Inc.

Recruiting

Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US)

Stage III Colon Cancer

United States, Canada
Qingdao Central Hospital

Recruiting

Osimertinib Combined With Bevacizumab in Patients With Brain Metastasis Epidermal Growth Factor Receptor (EGFR) Mutation Positive Metastatic Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

China
University of Crete
Galenica SA; Olvos Science SA

Completed

Assessment of the Clinical Effectiveness of a Herbal Extract (Cretan IAMA) in Patients With Viral Respiratory Infections, Including COVID-19, in Primary Healthcare Settings, and Co-assessment of Its Prophylactic Effect in People Cohabiting With These Patients (COVID-19-IAMA)

Covid19 | Respiratory Viral Infection | Viral Infection

Greece
Fujian Cancer Hospital

Recruiting

A Randomized Phase III Study Comparing POF With SOX/CAPOX/FOLFOX as a Postoperative Adjuvant Chemotherapy for Curatively Resected Stage III Gastric Cancer

Gastric Cancer Stage III

China
Sixth Affiliated Hospital, Sun Yat-sen University

Recruiting

ctDNA-guided Adjuvant Chemotherapy in Liver Metastasis of Colorectal Cancer

Colorectal Cancer | Chemotherapy Effect | Liver Metastases | Circulating Tumor Cell

China
Nanchong Central Hospital

Withdrawn

Apatinib for Resectable Colorectal Cancer

Colorectal Cancer | Surgery | Outcome, Fatal | Adjuvant Chemotherapy | Apatinib

China
National Cancer Institute (NCI)

Active, not recruiting

TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Serous Cystadenocarcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Recurrent... and other conditions

United States
Centre d'Investigation Clinique et Technologique...

Completed

Prognostic Value of Residual Hypoventilation in Mechanically Ventilated Neuromuscular Patients (TcCO2-VAD)

Neuromuscular Disease | Home Mechanical Ventilation

France
National Cancer Institute, Egypt

Completed

Prospective Study of Short Course Radiation Therapy Followed by Neoadjuvant Chemotherapy and Surgery in Locally Advanced Rectal Cancer

Locally Advanced Rectal Carcinoma

Egypt
Shanghai Hengrui Pharmaceutical Co., Ltd.

Recruiting

SHR-A1904 Combinations in CLDN18.2-Positive Advanced Solid Tumor

Cldn18.2-positive Advanced Solid Tumor

China
Shanghai Changzheng Hospital

Not yet recruiting

Preoperative Nivolumab Plus Bevacizumab Combined With Chemotherapy Before Surgery in Patients With pMMR/MSS Colorectal Cancer Liver Metastases

Colorectal Cancer Liver Metastases
Beijing Chao Yang Hospital

Recruiting

Camrelizumab Combined With Neoadjuvant Chemotherapy After Stent Placement for Left-Sided Obstructive Colonic Cancer (NACSOC-02)

Colorectal Cancer | Obstruction | Immunotherapy | Neoadjuvant Chemotherapy | Stent

China
Chung-Ang University

Completed

BReast CAncer Genes(BRCA) Expressions in Metastatic Gastric Cancer

BRCA Gene Rearrangement

Korea, Republic of
National Cancer Institute (NCI)
NRG Oncology

Completed

Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors

Glioblastoma | Gliosarcoma | Recurrent Glioblastoma | Oligodendroglioma | Giant Cell Glioblastoma | Recurrent Brain Neoplasm

United States, Canada
M.D. Anderson Cancer Center

Recruiting

Atezolizumab and Bevacizumab Before Surgery for the Treatment of Resectable Liver Cancer

Stage IB Hepatocellular Carcinoma AJCC v8 | Stage II Hepatocellular Carcinoma AJCC v8 | Resectable Hepatocellular Carcinoma | Stage I Hepatocellular Carcinoma AJCC v8 | Stage IA Hepatocellular Carcinoma AJCC v8

United States
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Recruiting

APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Clear Cell Adenocarcinoma | Fallopian Tube Clear Cell Adenocarcinoma | Fallopian Tube Endometrioid Adenocarcinoma | Fallopian Tube Serous Adenocarcinoma and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Ovarian Endometrioid Adenocarcinoma | Primary Peritoneal High Grade Serous Adenocarcinoma | Fallopian Tube Endometrioid Adenocarcinoma | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Ovarian High Grade Serous Adenocarcinoma | Platinum-Resistant... and other conditions

United States, Canada
Peking University Cancer Hospital & Institute
Peking University People's Hospital; Peking Union Medical College Hospital

Recruiting

Efficacy of Postoperative Adjuvant Chemotherapy for Stage II Colon Cancer With High Risk Factors(EPAC1) (EPAC1)

Adjuvant Chemotherapy

China
National Cancer Institute (NCI)

Completed

Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer

Cervical Adenocarcinoma | Cervical Adenosquamous Carcinoma | Cervical Squamous Cell Carcinoma, Not Otherwise Specified | Stage IVA Cervical Cancer AJCC v6 and v7 | Recurrent Cervical Carcinoma | Stage IV Cervical Cancer AJCC v6 and v7 | Stage IVB Cervical Cancer AJCC v6 and v7

United States
Northwestern University
National Cancer Institute (NCI); Ipsen Biopharmaceuticals

Completed

Irinotecan Liposome and Bevacizumab for the Treatment of Platinum Resistant, Recurrent, or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Platinum-Resistant Ovarian Carcinoma | Refractory Ovarian Carcinoma | Refractory Fallopian Tube... and other conditions

United States

Search clinical trials for: CapeOX bevacizumab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Liberia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations